瑞普生物：未来对宠物相关产品市场布局有信心，也将适度倾斜品牌宣传和市场推广费用

Core Viewpoint - The company expresses confidence in its future market positioning for pet-related products, leveraging its terminal advantages through the Zhongrui and Ruipai channels while focusing on mid-to-high-end market strategies [1] Group 1: Market Strategy - The company plans to increase brand promotion and marketing expenses to enhance its market presence [1] - Online channels are currently in a high-investment phase, with the acquisition of Hangzhou Zebra Bingbing's online promotion team and collaborations with top influencers to boost online sales [1] - Future offline efforts will focus on promoting biological products and auxiliary pharmaceuticals, while online efforts will emphasize pet deworming and health products [1] Group 2: Product Development - The company has launched new products this year, including "Chao Bi Xin" and "Miao Pu Jing" deworming medications, as well as the health product "En Qiu Er" [1] - Ongoing development includes new vaccines such as the cat trivalent live vaccine, cat quadrivalent mRNA vaccine, cat infectious peritonitis mRNA vaccine, and dog quadrivalent vaccine to continuously invigorate the pet segment [1]